Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPRI-424 (dienogest/ethinyl estradiol) for hirsutism in polycystic ovary syndrome
2021-002178-17Phase 3Completed
- Sponsor
- Chemo
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polycystic ovary syndrome (PCOS) and hirsutism comparing LPRI-424 with Placebo (2 arms). Primary endpoint: Change from baseline in adapted modified Ferriman-Gallwey (mFG) score. Started Jul 2021; status: completed.
02
Drugs
LPRI-424
03
Conditions
polycystic ovary syndrome (PCOS)hirsutism
Beyond the preview
Go deeper on 2021-002178-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002178-17.